Pet amiloide en la esclerosis múltiple
- Pytel, Vanesa
- Jorge Matías-Guiu Guía Directeur
- Jordi A. Matías-Guiu Directeur/trice
- María Nieves Cabrera Martín Directrice
Université de défendre: Universidad Complutense de Madrid
Fecha de defensa: 30 septembre 2019
- José Luis Carreras Delgado President
- Francisco Grandas Pérez Secrétaire
- Alfredo Rodríguez-Antigüedad Zarranz Rapporteur
- Mª Rosario Blasco Quílez Rapporteur
- Julián Benito León Rapporteur
Type: Thèses
Résumé
Multiple sclerosis (MS) is the most common demyelinating disease and the main cause of non-traumatic neurological disability in young adults. It is a clinically heterogeneous disease, including motor, cognitive and fatigue symptoms. This is the result of a combination of the main pathophysiological processes involved: inflammation, demyelination, axonal damage and neurodegeneration. In recent years, various disease-modifying therapies have been developed, aimed at acting on the immune system, with an anti-inflammatory effect that prevents relapses and slows the progression of disability...